Innovent

Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?
Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?
Fierce Biotech
Innovent
Eli Lilly
obesity
mazdutide
clinical trials
Flag link:
AACR 2023 – Moderna's immunotherapeutic splash
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
AACR
Moderna Therapeutics
Allogene
AstraZeneca
Merck
Roche
Novartis
Eli Lilly
Innovent
Springworks
Biogene
Relay Therapeutics
Vivace Therapeutics
Flag link:
Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial
Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial
Fierce Biotech
Innovent
AbbVie
JNJ
monoclonal antibodies
psoriasis
clinical trials
Flag link:
Looking east, Sanofi pens 'pioneering' cancer drug partnership with China's Innovent
Looking east, Sanofi pens 'pioneering' cancer drug partnership with China's Innovent
Fierce Biotech
Sanofi
China
oncology
cancer
Innovent
Flag link:
Innovent & Eli Lilly's Type 2 Diabetes Drug Lowers HbA1c, Scores Early Win
Innovent & Eli Lilly's Type 2 Diabetes Drug Lowers HbA1c, Scores Early Win
BioSpace
Innovent
Eli Lilly
type 2 diabetes
diabetes
mazdutide
clinical trials
Flag link:
Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data
Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data
Fierce Biotech
Innovent
Eli Lilly
Novo Nordisk
obesity
clinical trials
mazdutide
Flag link:
What now for low-cost PD-(L)1 competition?
What now for low-cost PD-(L)1 competition?
EP Vantage
FDA
anti-PD-L1
Innovent
Eli Lilly
Flag link:
Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's comments portend likely rejection
Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's comments portend likely rejection
Fierce Pharma
Eli Lilly
Innovent
Tyvyt
PD-1 inhibitors
Flag link:
Good news for Lilly as sintilimab hits the spot in lung cancer again
Good news for Lilly as sintilimab hits the spot in lung cancer again
Pharmaforum
Eli Lilly
China
Innovent
sintilimab
non-squamous non-small cell lung cancer
non-small cell lung cancer
Flag link:
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option
Pharmaforum
Eli Lilly
Innovent
China
sintilimab
Keytruda
Merck
immunotherapy
Flag link:
Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Endpoints
Junshi Biosciences
China
Merck
Innovent
nasopharyngeal carcinoma
toripalimab
Flag link: